Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa | Zendy

Jocelyn Qi-Min Teo | Zendy; Jie Chong Lim | Zendy; Cheng Yee Tang | Zendy; Shan Jing-Yi Lee | Zendy; Si Hui Tan | Zendy; James Heng-Chiak Sim | Zendy; Rick TweeHee Ong | Zendy; Andrea LayHoon Kwa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa

Author(s) -

Jocelyn Qi-Min Teo,

Jie Chong Lim,

Cheng Yee Tang,

Shan Jing-Yi Lee,

Si Hui Tan,

James Heng-Chiak Sim,

Rick TweeHee Ong,

Andrea LayHoon Kwa

Publication year - 2021

Publication title -

msphere

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.749

H-Index - 39

ISSN - 2379-5042

DOI - 10.1128/msphere.01026-20

Subject(s) - pseudomonas aeruginosa , microbiology and biotechnology , biology , ceftazidime/avibactam , genotype , multiple drug resistance , ceftazidime , drug resistance , bacteria , gene , genetics

Pseudomonas aeruginosa infection is one of the most difficult health care-associated infections to treat due to the ability of the organism to acquire a multitude of resistance mechanisms and express the multidrug resistance phenotype. Ceftolozane/tazobactam (C/T), a novel β -lactam/ β -lactamase inhibitor combination, addresses an unmet medical need in patients with these multidrug-resistant P. aeruginosa infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research